Extended Data Table 3 Association among clinical characteristics and CH mutational characteristics

From: Cancer therapy shapes the fitness landscape of clonal hematopoiesis

Variable (reference)

 

OR

95% CI

p

Age

–

1

1–1.1

0.0011

Ethnicity (white)

Asian

1

0.94–1.2

0.42

Black

0.9

0.82–1

0.053

Other

0.93

0.83–1

0.24

Unknown

0.92

0.8–1.1

0.22

Smoke (non-smoker)

Smoker

1.1

1.1–1.2

0.000023

Therapy (untreated)

Treated

1

0.96–1.1

0.8

PD status (non-PD non-myeloid)

Myeloid PD

1.3

1.3–1.4

< 1 × 10−6

Non-myeloid PD

1.3

1.2–1.5

0.000052

Non-PD myeloid

0.99

0.92–1.1

0.8

Number of mutations (1)

≥ 2

1.1

1.1–1.2

0.0000038

  1. Myeloid PD, genes mutated in myeloid neoplasms; non-myeloid, genes not linked to myeloid neoplasms; myeloid PD, variants known to be myeloid drivers or putative somatic driver mutations in myeloid neoplasms; myeloid non-PD, mutations within genes linked to myeloid neoplasms but that are not putative drivers; non-myeloid PD, mutations that are putative somatic driver mutations of cancer in genes not linked to myeloid neoplasms; non-myeloid non-PD, mutations within genes not linked to myeloid neoplasms that are not putative drivers of cancer. Associations were evaluated using multivariable logistic regression models to generate heterogeneity p-values. Sensitivity analyses restricted to individuals with only one mutation yielded similar results. Age expressed in decile.
Back to article page